Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $10.9 million.

  • Janux Therapeutics' Non Operating Income rose 4053.71% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year increase of 6673.09%. This contributed to the annual value of $29.9 million for FY2024, which is 10327.52% up from last year.
  • As of Q3 2025, Janux Therapeutics' Non Operating Income stood at $10.9 million, which was up 4053.71% from $11.3 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Non Operating Income high stood at $11.4 million for Q1 2025, and its period low was $46000.0 during Q2 2021.
  • In the last 5 years, Janux Therapeutics' Non Operating Income had a median value of $3.7 million in 2023 and averaged $4.6 million.
  • In the last 5 years, Janux Therapeutics' Non Operating Income surged by 287432.43% in 2022 and then soared by 4053.71% in 2025.
  • Janux Therapeutics' Non Operating Income (Quarter) stood at $74000.0 in 2021, then surged by 2874.32% to $2.2 million in 2022, then soared by 98.96% to $4.4 million in 2023, then soared by 101.1% to $8.8 million in 2024, then rose by 24.21% to $10.9 million in 2025.
  • Its Non Operating Income was $10.9 million in Q3 2025, compared to $11.3 million in Q2 2025 and $11.4 million in Q1 2025.